News
)
4 May 2022
Interview with Natalia Elizalde in The Medicine Maker
The Business Development Director of VIVEbiotech Dr. Natalia Elizalde was interviewed by The Medicine Maker on the challenges of lentiviral vector manufacture/use.
Read more)
2 May 2022
Gurutz Linazaroso, the CEO of VIVEbiotech, in the Medicine Maker Power List 2022
The CEO of VIVEbiotech, Dr. Gurutz Linazasoro, is part of the prestigious The Medicine Maker Power List
Read more)
7 April 2022
The Analytical Scientist interviews Rakel Lopez de Maturana
The Analytical Scientist interviewed Rakel Lopez de Maturana, VIVEbiotech´s Qualified Person & Regulatory Affairs Director.
Read more)
9 March 2022
PharmaBoardroom interviews Gurutz Linazasoro, CEO of VIVEbiotech
PharmaBoardroom, the global platform for healthcare & life sciences executives, interviewed Gurutz Linazasoro, CEO of VIVEbiotech.
Read more)
18 February 2022
VIVEbiotech receives the “LH Duala Euskaraz” award
VIVEbiotech has been awarded with the “LH Duala Euskaraz” prize for promoting the use of Euskara, the language of the Basque Country, on a regular...
Read more)
2 February 2022
PharmaBoardoom points out VIVEbiotech as one of the ten Spanish Biotechs to watch in 2022
PharmaBoardroom, a leading British media specialized in the health sector, has published an article in which it highlights VIVEbiotech as one of the ten Spanish...
Read more)
5 January 2022
Article on improving viral vector production in GEN
GEN recently interviewed our Business Development Director, Dr. Natalia Elizalde, with whom they spoke about improving the production of lentiviral vectors, vectors that VIVEbiotech develops...
Read more)
)
26 November 2021
Gurutz Linazasoro has been awarded a 2021 Korta Award
The CEO of VIVEbiotech, Gurutz Linazasoro, has received one of the four 2021 Korta Awards delivered this past Wednesday by the Lehendakari Iñigo Urkullu.
Read more)
28 October 2021
Successful participation of VIVEbiotech in five international meetings in the last half of the year
VIVEbiotech has participated very successfully in five international meetings since the summer.
Read moreDestacadas
)
)
)
)
)
)
)
)
)
23 August 2024
)